Leflunomide-d4 – 500 µg

Brand:
Cayman
CAS:
1189987-23-2
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

Leflunomide-d4 is intended for use as an internal standard for the quantification of leflunomide (Item No. 14860) by GC- or LC-MS. Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 (Item No. 14404), a dihydroorotate dehydrogenase inhibitor.{22723} Leflunomide inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle. It inhibits proliferation and activation of T cells when used at concentrations of 25 and 100 µM, respectively, for naïve and memory CD4+ T cells.{46073} It also reduces the production of Th1 effector cells and increases differentiation of Th2 cells in vitro and in splenocytes isolated from KLH-immunized mice. Leflunomide (35 mg/kg per day) reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis.{46074} Formulations containing leflunomide have been used in the treatment of active rheumatoid arthritis.  

 

Available on backorder

SKU: 26448 - 500 µg Category:

Description

An internal standard for the quantification of leflunomide by GC- or LC-MS


Formal name: 5-methyl-N-(4-(trifluoromethyl)phenyl-2,3,5,6-d4)isoxazole-4-carboxamide

Synonyms: 

Molecular weight: 274.2

CAS: 1189987-23-2

Purity: ≥99% deuterated forms (d1-d4)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Innate Immunity